A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma

Trial Profile

A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Bortezomib; Ibritumomab tiuxetan; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 09 Jan 2012 Actual patient number is 12 according to ClinicalTrials.gov.
    • 09 Jan 2012 Actual end date (1 Oct 2011 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top